Compare ADCT & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADCT | PLBY |
|---|---|---|
| Founded | 2011 | 1953 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.1M | 128.3M |
| IPO Year | 2019 | 2020 |
| Metric | ADCT | PLBY |
|---|---|---|
| Price | $1.13 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $7.75 | $3.00 |
| AVG Volume (30 Days) | ★ 796.4K | 669.2K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.86 | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | $81,357,000.00 | ★ $120,928,000.00 |
| Revenue This Year | N/A | $9.17 |
| Revenue Next Year | $66.49 | $7.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.85 | 4.13 |
| 52 Week Low | $0.78 | $1.08 |
| 52 Week High | $4.98 | $2.75 |
| Indicator | ADCT | PLBY |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 46.72 |
| Support Level | $1.03 | $1.09 |
| Resistance Level | $1.17 | $1.30 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 41.18 | 42.50 |
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.